120 related articles for article (PubMed ID: 26545298)
41. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia.
Usall J; Suarez D; Haro JM;
Psychiatry Res; 2007 Dec; 153(3):225-31. PubMed ID: 17681611
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
43. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
[TBL] [Abstract][Full Text] [Related]
44. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment.
Song HT; Sun XY; Zhang L; Zhao L; Guo ZM; Fan HM; Zhong AF; Niu W; Dai YH; Zhang LY; Shi Z; Liu XP; Lu J
J Psychiatr Res; 2014 Jul; 54():134-40. PubMed ID: 24694668
[TBL] [Abstract][Full Text] [Related]
45. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
Liu-Seifert H; Osuntokun OO; Feldman PD
Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
[TBL] [Abstract][Full Text] [Related]
46. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
47. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
48. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
Düring S; Glenthøj BY; Oranje B
Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
[TBL] [Abstract][Full Text] [Related]
49. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
[TBL] [Abstract][Full Text] [Related]
50. Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.
Rabinowitz J; Werbeloff N; Caers I; Mandel FS; Stauffer V; Ménard F; Kinon BJ; Kapur S
J Clin Psychiatry; 2014 Apr; 75(4):e308-16. PubMed ID: 24813414
[TBL] [Abstract][Full Text] [Related]
51. WEIGHT GAIN AND ANTIPSYCHOTICS. DATA FROM EUFEST STUDY.
Matei VP; Mihailescu A; Paraschiv G; Al-Bataineh R; Purnichi T
Acta Endocrinol (Buchar); 2016; 12(2):177-184. PubMed ID: 31149084
[TBL] [Abstract][Full Text] [Related]
52. The SWITCH study: rationale and design of the trial.
Heres S; Cirjaliu DM; Dehelean L; Matei VP; Podea DM; Sima D; Stecher L; Leucht S
Eur Arch Psychiatry Clin Neurosci; 2016 Sep; 266(6):513-21. PubMed ID: 26227799
[TBL] [Abstract][Full Text] [Related]
53. How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis.
Zhu Y; Li C; Huhn M; Rothe P; Krause M; Bighelli I; Schneider-Thoma J; Leucht S
Eur Neuropsychopharmacol; 2017 Sep; 27(9):835-844. PubMed ID: 28669774
[TBL] [Abstract][Full Text] [Related]
54. PROLACTIN LEVEL IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA TREATED FOR ONE YEAR WITH ATYPICAL ANTIPSYCHOTICS.
Matei VP; Purnichi T; Mihailescu A; Grigoras R
Acta Endocrinol (Buchar); 2018; 14(4):483-490. PubMed ID: 31149301
[TBL] [Abstract][Full Text] [Related]
55. Gender differences in patients with first-episode psychosis in the Singapore Early Psychosis Intervention Programme.
Pang S; Subramaniam M; Abdin E; Poon LY; Chong SA; Verma S
Early Interv Psychiatry; 2016 Dec; 10(6):528-534. PubMed ID: 25601015
[TBL] [Abstract][Full Text] [Related]
56. Analysis of color vision and cognitive function in first-episode schizophrenia before and after antipsychotic treatment.
Duan L; Tian C; Fu C; He J; Dai J; Shao X; Zhu G
J Psychiatr Res; 2022 Aug; 152():278-288. PubMed ID: 35759980
[TBL] [Abstract][Full Text] [Related]
57. Gender differences in outcomes of early intervention services for first episode psychosis.
Hong SI; Bennett D; Rosenheck RA
Early Interv Psychiatry; 2023 Jul; 17(7):715-723. PubMed ID: 36623822
[TBL] [Abstract][Full Text] [Related]
58. Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria.
Ezeme MS; Uwakwe R; Ndukuba AC; Igwe MN; Odinka PC; Amadi K; Obayi NO
Afr Health Sci; 2016 Dec; 16(4):1036-1044. PubMed ID: 28479897
[TBL] [Abstract][Full Text] [Related]
59. Obstetric complications predict treatment response in first-episode schizophrenia.
Alvir JM; Woerner MG; Gunduz H; Degreef G; Lieberman JA
Psychol Med; 1999 May; 29(3):621-7. PubMed ID: 10405083
[TBL] [Abstract][Full Text] [Related]
60. Aldosterone and aldosterone/cortisol ratio is higher in serum of long-term compared to first episode schizophrenia patients: A pilot study.
Ustohal L; Hlavacova N; Mayerova M; Ceskova E; Jezova D
J Psychiatr Res; 2018 Sep; 104():46-49. PubMed ID: 29940461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
